Third Derivative Suit Names CEO, CFO, and 10 Directors; Alleges $4.7M in Insider Sales During Misleading Disclosures
FSK sits 24% above its 52-week low of $9.72.
Summary
A third shareholder derivative lawsuit names all 12 officers and directors of FS KKR Capital, alleging fiduciary breaches and adding new insider-sale claims: CEO Forman sold ~$3.8M and director Imasogie sold ~$900K (84% of his holdings) during the period of allegedly misleading disclosures.
Key Events · Legal and Risk Events · FSK
-
Third Derivative Complaint Filed
Joseph M. Bruno filed a verified shareholder derivative complaint on August 21, 2026 in E.D. Pa. (Case No. 2:26-cv-06159-CFK) against all 12 current and former officers and directors of FS KKR Capital.
-
Insider Sales Alleged During Misleading Disclosures
CEO Michael Forman sold 195,139 shares for ~$3,816,431 on Aug 15, 2024 at $19.5575/share; director Osagie Imasogie sold 40,885 shares for ~$900,034 on Nov 25, 2024 at ~$22.01/share, reducing his holdings by 84%.
-
Claims Include Proxy Violations and Contribution
The complaint asserts Section 14(a) proxy violations against 11 director-defendants and seeks contribution under Sections 10(b)/21D from Forman and CFO Lilly for any liability in the related securities class action.
-
Demand Futility Alleged for 8 of 11 Directors
Plaintiff alleges demand on the board is excused because 8 of 11 directors face substantial likelihood of personal liability, including those on the Valuation and Audit Committees.
Analysis · FSK · Unknown
A new shareholder derivative complaint filed August 21, 2026 in the Eastern District of Pennsylvania names all 12 current and former officers and directors of FS KKR Capital, including CEO Michael Forman, CFO Steven Lilly, and President/CIO Daniel Pietrzak. The complaint alleges breaches of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of Section 14(a) of the Exchange Act. Critically, it adds new insider-sale allegations: Forman sold 195,139 shares for approximately $3.8 million on August 15, 2024, and director Osagie Imasogie sold 40,885 shares for approximately $900,000 on November 25, 2024, reducing his holdings by 84%, while the company was allegedly making misleading statements about portfolio restructuring and valuation. The complaint also seeks contribution from Forman and Lilly under Sections 10(b) and 21D for any liability the company incurs in the related securities class action. This is the third derivative action against the company in the last 90 days, but the first to name individual defendants and allege timed insider sales, materially expanding the company's litigation exposure and governance scrutiny.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FSK was trading at $12.05 on NYSE in the Unknown sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $9.72 to $18.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.